基石药业-B(02616.HK) 公布，已向欧洲药品管理局提交舒格利单抗的新适应症申请，用于治疗同步或序贯放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌(NSCLC)患者。
若顺利获批，舒格利单抗将填补III期非小细胞肺癌这一疾病领域的关键需求，成为欧洲第二款治疗该适应症的PD-(L)1抗体。同时，舒格利单抗在III期和IV期非小细胞肺癌中的双重应用，将进一步巩固其作为肺癌核心免疫疗法的地位。
基石药业首席执行官、研发总裁及执行董事杨建新表示，基于突出的疗效与良好的安全性，舒格利单抗有望解决III期NSCLC患者极待满足的临床需求。另外，公司将继续深化国际战略合作，并与监管机构紧密协作，以提高舒格利单抗在全球范围内的可及性。(js/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.